Petar Vukovic,Milan Milojevic,Slobodan Micovic et al. Petar Vukovic et al.

This case underscores the value of patient-specific minimally invasive approaches and advanced valve technology in complex redo aortic valve procedures.

Muhammad Talha,Maliha Khalid,Muammar Hassan et al. Muhammad Talha et al.

Peng Liu,Hanzhe Wang,Shijie Wang et al. Peng Liu et al.

While curative treatments exist, advancements in therapeutic approaches and prosthetic valve technology continue to evolve.

Deniz Mutlu,Ibrahim Halil Inanc,Ozgecan Piril Zanbak Mutlu et al. Deniz Mutlu et al.

The absence of a Food and Drug Administration-approved percutaneous valve technology for the treatment of severe aortic regurgitation (AR) presents a challenge for high-risk patients.

Dylan Goode,Lawrence Scotten,Rolland Siegel et al. Dylan Goode et al.

This study highlights the iValve's potential to revolutionize prosthetic heart valve technology by offering a durable, hemodynamically superior solution that mitigates the drawbacks of current MHVs.

Jessica A Schults,Tricia Kleidon,Karina Charles et al. Jessica A Schults et al.

Integrated valve technology compared to no valve technology for peripherally inserted central catheter design Integrated valve technology may make little or no difference to VTE risk when compared with PICCs with no valve (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.19 to 2.63; I² = 0%; 3 studies...We are uncertain whether integrated valve technology reduces PICC-associated BSI risk, as the certainty of the evidence is very low (RR 0.20, 95% CI 0.01 to 4.00; I² = not applicable; 2 studies (no events in 1 study); 257 participants)....Integrated valve technology may make little or no difference to occlusion risk when compared with PICCs with no valve (RR 0.86, 95% CI 0.53 to 1.38; I² = 0%; 5 studies; 900 participants; low certainty evidence)....We are uncertain whether use of integrated valve technology reduces all-cause mortality risk, as the certainty of evidence is very low (RR 0.85, 95% CI 0.44 to 1.64; I² = 0%; 2 studies; 473 participants)....Integrated valve technology may make little or no difference to catheter failure risk when compared with PICCs with no valve (RR 0.80, 95% CI 0.62 to 1.03; I² = 0%; 4 studies; 720 participants; low certainty evidence).

Farrah Othman,Gerald Yong,Alan Whelan et al. Farrah Othman et al.

Percutaneous management of native pure aortic regurgitation is difficult due to anatomical challenges and the limitations of current transcatheter heart valve technology to anchor in the absence of leaflet or annular calcification.

Zeki Çetinkaya,Deniz Elçik,Şaban Keleşoğlu et al. Zeki Çetinkaya et al.

Background/aim: Despite advancements in valve technology and increased clinical experience, complications related to conduction defects after transcatheter aortic valve implantation (TAVR) have not improved as rapidly as expected.

Nicholas M Fialka,Ryaan El-Andari,Shaohua Wang et al. Nicholas M Fialka et al.

Objective: The surgical treatment of aortic stenosis continues to evolve, and sutureless aortic valve replacement (SUAVR) is an emerging technology. With the Perceval S (Corcym, London, UK) as the only true sutureless val...

Sarida Naorungroj,Chawin Srisomwat,Wisarut Khamcharoen et al. Sarida Naorungroj et al.

To enable automation, the DNAzyme-based assay was combined with a capillary-driven microfluidic device featuring a burst valve technology to allow sequential sample and reagent delivery as well as the DNA target hybridization and enzymatic reaction to be operated in a precisely controlled fashion.